Operating Cash Flow per Share: A measure of financial performance calculated as operating cash flow, expressed on a per share basis. Calculated as: Cash Flow from Operations / Weighted Average Shares Outstanding (Diluted)
Amylyx Pharmaceuticals, Inc. (AMLX) had Operating Cash Flow per Share of $-0.46 for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-35.91M |
|
-- |
|
-- |
|
$37.80M |
|
$-37.80M |
|
$1.90M |
|
$-35.91M |
|
$-35.91M |
|
$-35.91M |
|
$-35.91M |
|
$-35.91M |
|
$-35.91M |
|
$-37.80M |
|
$-39.35M |
|
85.70M |
|
85.70M |
|
$-0.42 |
|
$-0.42 |
|
| Balance Sheet Financials | |
$216.14M |
|
$0.82M |
|
$3.53M |
|
$219.68M |
|
$17.93M |
|
-- |
|
$0.33M |
|
$18.26M |
|
$201.42M |
|
$201.42M |
|
$201.42M |
|
89.08M |
|
| Cash Flow Statement Financials | |
$-39.82M |
|
$-43.66M |
|
$65.66M |
|
$78.84M |
|
$61.21M |
|
$-17.62M |
|
$6.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.05 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-39.84M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.83% |
|
-17.83% |
|
-16.35% |
|
-17.83% |
|
$2.26 |
|
$-0.46 |
|
|
Operating Cash Flow per Share |
$-0.46 |